At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 351 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp
In Brief
A Phase 3 clinical trial evaluating Placebo and KX2-391 Ointment 1% for Actinic Keratoses. Completed, enrolled 351 participants across 30 sites.
Detailed Summary
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesUnited States
CollaboratorsAthenex, Inc.
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartSep 2017
Primary CompletionMay 2018
Study CompletionApr 2019
TodayJul 2026
First PostedSep 18, 2017
Enrollment StartSep 18, 2017
Primary CompletionMay 3, 2018
Study CompletionApr 24, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.8 years ago
Interventions
Placebodrug
Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
KX2-391 Ointment 1%drug
The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.